Alkeon Capital Management
MREO

Alkeon Capital Management’s Mereo BioPharma MREO Stock Holding History

Alkeon Capital Management’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,698,100
Closed -$7.62M – 121
2025
Q3 		$7.62M Sell
3,698,100
-1,000,000
-21% -$1.84M 0.01% 104
2025
Q2 		$12.7M Hold
4,698,100
– – 0.02% 92
2025
Q1 		$10.6M Hold
4,698,100
– – 0.02% 95
2024
Q4 		$16.4M Hold
4,698,100
– – 0.03% 84
2024
Q3 		$19.3M Hold
4,698,100
– – 0.03% 83
2024
Q2 		$16.9M Buy
4,698,100
+460,000
+11% +$1.49M 0.03% 93
2024
Q1 		$14M Hold
4,238,100
– – 0.02% 90
2023
Q4 		$9.79M Buy
4,238,100
+500,000
+13% +$956K 0.02% 88
2023
Q3 		$4.82M Hold
3,738,100
– – 0.01% 98
2023
Q2 		$4.93M Buy
3,738,100
+1,352,500
+57% +$1.57M 0.01% 112
2023
Q1 		$1.69M Buy
2,385,600
+250,000
+12% +$225K ﹤0.01% 126
2022
Q4 		$1.6M Hold
2,135,600
– – 0.01% 127
2022
Q3 		$1.84M Buy
2,135,600
+400,000
+23% +$489K 0.01% 133
2022
Q2 		$1.94M Sell
1,735,600
-200,000
-10% -$155K 0.01% 142
2022
Q1 		$2.17M Hold
1,935,600
– – ﹤0.01% 143
2021
Q4 		$3.1M Hold
1,935,600
– – 0.01% 148
2021
Q3 		$4.68M Hold
1,935,600
– – 0.01% 168
2021
Q2 		$6.14M Hold
1,935,600
– – 0.01% 166
2021
Q1 		$6.52M Hold
1,935,600
– – 0.01% 158
2020
Q4 		$6.93M Buy
+1,935,600
New +$4.85M 0.01% 152

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Alkeon Capital Management's MREO Position: Q4 2025 in Review

Alkeon Capital Management sold out of Mereo BioPharma (MREO) in Q4 2025, closing a stake of 3,698,100 shares — an estimated $7.62M sold.

Alkeon Capital Management first reported a position in MREO in Q4 2020 and held it in 20 quarters. The position peaked at $19.3M in Q3 2024. 70 funds tracked by Wall St. Rank hold MREO as of Q4 2025.

  • Alkeon Capital Management reported no remaining Mereo BioPharma position as of Q4 2025 after selling out during the quarter.
  • Alkeon Capital Management sold 3,698,100 Mereo BioPharma shares in Q4 2025, an estimated $7.62M.
  • Alkeon Capital Management first reported a position in Mereo BioPharma in Q4 2020 and held it in 20 quarters.
  • Alkeon Capital Management's Mereo BioPharma position peaked at $19.3M in Q3 2024.
  • 70 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2025.

Based on Alkeon Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.